Kentucky Kroger closes aisle after possible rodent infestation

LEXINGTON, Ky. (FOX 56) — A possible rodent infestation is being investigated at a Louisville Kroger store.
WDRB reported that the Louisville Health Department is investigating the Goss Avenue Kroger after evidence of a rodent infestation was found in three aisles, including bread and pasta products.
Kentucky Kroger closes aisle after possible rodent infestation
Beshear activates Emergency Operations Center ahead of 'No Kings' protests
Lexington 'No Kings' rally to remain peaceful amid anti-ICE protests in LA
The health department has ordered the store to close the affected aisles, remove everything from the shelves, and break them down to get rid of the pests.
A Kroger spokesperson said the company worked with the Health Department to fully resolve the issue and ensure the store meets the highest standards of cleanliness and safety.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

6 hours ago

• Yahoo

Conspiracy Theorists Are Creating Special AIs to Agree With Their Bizarre Delusions

Conspiracy theorists are using AI chatbots not only to convince themselves of their harebrained beliefs, but to recruit other users on social media. As independent Australian news site Crikey reports, conspiracy theorists are having extensive conversations with AI chatbots to "prove" their beliefs. Then, they post the transcripts and videos on social media as "proof" to others. According to the outlet's fascinating reporting, there are already several bots specifically trained on harebrained conspiracy theories, including a custom bot designed to convince parents not to vaccinate their children. The news highlights a troubling trend, with countless ChatGPT users developing bizarre delusions and even spiraling into severe mental health crises, as we reported last week. Experts have warned that AI chatbots are designed to be incredibly sycophantic, predisposing them to agreeing with users even when doing so is clearly harmful. Much like delusions of spiritual awakenings, messianic complexes, and boundless paranoia, conspiracy theorists are finding the perfect conversational partner in tools like ChatGPT. Since they were trained on the open web — an enormous data set that includes unfounded conspiracy theories, like the belief that vaccines cause autism — they can easily be coaxed into furthering these theories. As Crikey reports, one chatbot called Neo-LLM was trained by a Texan anti-vaxxer using over 100,000 dubious articles from the far-right conspiracy theory news website Natural News. It's unclear how many users have downloaded the chatbot, but promotional videos have garnered tens of thousands of views. In short, it's an alarming trend that shows the dangers of powerful AI chatbot tech falling into the wrong hands. In particular, people suffering from mental health issues can be convinced they're talking to a real authority, rather than a parroting language model that continuously calculates the probability of the next word. That kind of delusion can have devastating consequences. As the New York Times reported last week, a 35-year-old man — who had previously been diagnosed with bipolar disorder and schizophrenia before becoming obsessed with ChatGPT — was shot and killed by police after he charged at them with a knife following a mental health crisis centering on the bot. Since AI chatbots have become incredibly effective at generating convincing-sounding answers, their ill use could have real-life implications. Researchers have shown that AI chatbots can easily be weaponized and taught how to spew an endless firehose of disinformation. With the Trump administration actively rolling back AI regulations and key politicians furthering anti-vaccine conspiracy theories themselves, the future looks bleak. Even tech companies have historically failed to implement effective guardrails to stop chatbots from hallucinating. However, some experts have pondered if the tech could be used for good as well. Last year, researchers at MIT found that chatbots can also be used to reduce the belief in conspiracy theories, a glimmer of hope as the internet becomes increasingly polluted with deranged, AI-generated claims. More on AI delusions: People Are Becoming Obsessed with ChatGPT and Spiraling Into Severe Delusions

Business Upturn

9 hours ago

• Business Upturn

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

By GlobeNewswire Published on June 23, 2025, 00:35 IST New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1 . . Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1 . . FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system 2 . . These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3. Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. In the study, the first Mim8 maintenance dose was administered on the next planned emicizumab dosing day. Patients were given the option of switching to once-monthly, once every two weeks or once-weekly dosing frequencies of Mim8, regardless of their prior dosing frequency1,3. Steady-state Mim8 concentration was achieved by Week 16, and emicizumab elimination was completed by Week 261. Switching to Mim8 led to a sustained increase in thrombin peak levels without an exaggerated thrombin response1. 'Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with haemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period,' said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. 'This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease.' The open-label phase 3b FRONTIER5 study consisted of 61 adults and adolescents, aged 12 years and older, with haemophilia A. Mim8 was well-tolerated with no safety concerns. No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no clinical evidence of neutralising anti-Mim8 antibodies1. The PROs data from FRONTIER5 indicated a strong overall preference for the Mim8 pen-injector, with 97% (n=57/59) of patients reporting a 'very strong' or 'fairly strong' preference in comparison to their previous emicizumab injection system2. Of the participants who completed the Haemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector 'very easy' or 'easy' to use, and 95% (n=56/59) found it 'much easier' or 'easier' compared with their previous administration method. All participants (100%) were 'extremely confident' or 'very confident' in using the pen-injector correctly, and most participants (83%; n=49/59) found it 'very easy' to inject the dose2. 'The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with haemophilia A and demonstrate our continued commitment to developing innovative treatment options for this community', said Stephanie Seremetis, chief medical officer and CVP for Haemophilia at Novo Nordisk. 'These results give valuable insights into haemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device.' Novo Nordisk expects to submit Mim8 for regulatory review during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026. About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding4. It is estimated to affect approximately 1,125,000 people worldwide5. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing4. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX4. Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe haemophilia A develop inhibitors6 that can cause replacement therapies to stop working. About Mim8 Mim8 is an investigational FVIIIa mimetic bispecific antibody optimised with the aim to deliver improved potency and sustained efficacy across flexible dosing intervals up to once-monthly prophylaxis for people living with haemophilia A, with or without inhibitors7-10. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity into the normal range, helping blood to clot7,11. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trial FRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with haemophilia A, with or without inhibitors3. The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER53,12-15. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Available at: Last accessed: June 2025. MedlinePlus. Hemophilia. Available at: Last accessed: June 2025. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. doi: 10.5045/br.2019.54.3.204. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. doi: 10.1182/blood.2020010331. Mancuso EM, et al. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Abstract presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress. Kenet G, et al. Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study. Abstract presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 Annual Congress. Session 6. Chowdary P, Banchev AM, Kavakli K, et al. Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study. Abstract presented at the American Society of Hematology (ASH) 2024 Annual Congress. Session: 322. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Available at Last accessed: June 2025. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Available at: Last accessed: June 2025. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Available at: Last accessed: June 2025. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

The Hill

a day ago

• The Hill

Health care workers on alert for ICE raids in hospitals

President Trump's whittling away of protected places for immigrants has fueled fears among health care workers that Immigration and Customs Enforcement (ICE) agents will arrest patients in or around hospitals. In January, the Trump administration rescinded a Biden-era policy that protected certain areas like churches, schools and hospitals from immigration enforcement. And lawmakers in at least one state have introduced legislation aimed at making it easier for ICE to make arrests in hospitals. As the Department of Homeland Security (DHS) seeks to ramp up ICE raids at hotels, restaurants, farms and other sites, nurses worry their workplace could be next. 'We were all worried about what this meant,' Michael Kennedy, a nurse at a University of California, San Diego health facility located very near the U.S.-Mexico border, said of the policy changes under Trump. 'As we've seen these immigration raids ramp up, our first thought is about our patients and what that means for them.' ICE agents made a record number of migrant arrests in a single day this month and have appeared outside of courthouses in Seattle and stores in the New York City area. The agency's workplace raids in Los Angeles spurred days of protests, which in turn prompted a heavy-handed response from the Trump administration. Sandy Reding is a nurse at a hospital in Bakersfield, Calif., which serves communities of farm workers and employs a diverse staff. 'There is a lot of concern [about] ICE agents showing up with FBI or with the military, because we've seen a lot of reports on TV, and we have reports in our area where this is happening as well,' she said. Reding and her fellow nurses, she said, are also worried that the news of increased ICE raids will deter some patients from coming to the hospital to seek care. 'What we are going to see is a large burden on communities and hospitals if people delay care,' Reding said. 'And there are worse outcomes.' Nancy Hagan, an intensive care unit nurse at Maimonides Medical Center in New York City, said those concerns have come to fruition at her hospital. In May, she said, an immigrant New Yorker had appendicitis but waited too long to go to the emergency room. Their appendix burst, spreading infected tissue and bacteria to other organs, which ultimately killed them. 'Once patients hear that a hospital is no longer a safe place for them to go, they are afraid to come to the hospital,' she said. Hagan, a Haitian immigrant, added that she and her colleagues, who work at hospitals across the city, have noticed that emergency rooms appear to be emptier in recent months. Kennedy, the nurse in San Diego, said the Level 1 trauma center, which is typically packed, has been emptier than usual. He admitted the decline in patient visits could be seasonally related, but he said he believes that the possibility of ICE agents arresting immigrants is having a 'chilling effect.' 'I can't see how this doesn't affect our patients' willingness to seek care,' he said. 'I'm willing to bet that a lot of people are delaying care because they're afraid.' ICE did not get back to The Hill in response to questions on whether agents have arrested people in or around hospitals, or if there are plans to do so. DHS announced in January that it had rescinded former President Biden's guidelines on immigration enforcement at 'sensitive locations' that were first issued under former President Obama. 'The Trump Administration will not tie the hands of our brave law enforcement, and instead trusts them to use common sense,' a DHS spokesperson said at the time. The National Immigration Law Center said that while immigrants no longer have special protections at hospitals and other 'sensitive locations,' they still have basic rights. 'Instead, individuals will need to rely on basic constitutional protections in these spaces,' it said in a fact sheet. 'Specifically, the Fourth Amendment protects all individuals from unreasonable searches and seizures, and the Fifth Amendment ensures the right to remain silent when confronted by law enforcement.' The Emergency Medicine Residents' Association has distributed a flyer with step-by-step guidance for health care workers on dealing with ICE agents if they do enter hospitals.